johnson & johnson account deep dive analysis - amazon s3 · johnson & johnson –account...

Source : DRAUP

1

1

Johnson & Johnson – Account Deep Dive

Analysis

October 2018

Source : DRAUP

2

2

AGENDA

➢ Johnson & Johnson Overview

❑ Highlights on Johnson & Johnson, business overview

❑ Last 5 years revenue analysis

❑ Revenue split by geography

❑ Key operating business segment

➢ Organization Structure

❑ CXO’s and Executives

Rolodex04

Account Profile

Business & Financial Overview

Outsourcing Vendor Analysis

Globalization Footprint

Recommendations05

01

02

03

Source : DRAUP

3

3

On October 2, 2018 Johnson & Johnson completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion

Revenue in $ billion R&D spend in $ billion

Johnson & Johnson, together with its subsidiaries,

researches and develops, manufactures, and sells

various products in the health care field worldwide. It

is an American multinational medical devices,

pharmaceutical and consumer packaged goods

manufacturing company.

About Johnson & Johnson

Note – DRAUP data curated from Johnson & Johnson financial reports published annually and updated in October, 2018

Revenue (2017):USD $ 76.45 billion

R&D Spend (2017):USD $ 10.55 billion

Headquarter:New Brunswick, New Jersey,

United States

Year of Establishment:1887

Revenue vs R&D spend (2013-17)

Revenue CAGR

(2013 - 2017):1.76%

R&D CAGR

(2013 - 2017):6.57%

Revenue share by segment (2017)

Employees (2017):~ 1,34,000

Revenue share by Geography (2017)

52%

22%

18%

8%

United States

Europe

Asia-Pacific, Africa

WesternHemisphere

Pharmaceutical47%

Medical devices35%

Consumer18%

$71.31 $74.33

$70.07 $71.89 $76.45

$8.18 B $8.49 B $9.04 B $9.09 $10.55

2013 2014 2015 2016 2017

Source : DRAUP

4

4

Johnson & Johnson – Business Segments Overview

Johnson & Johnson

Accelerant

Note – DRAUP data curated from Johnson & Johnson financial and analysts reports published annually and updated in October, 2018

ACUVUE Adjunctive HemostasisAccessAdvanced Sterilization

Products (ASP)

Automotive Experience Building EfficiencyChemical Process

Equipment's & EngineeringBiosense Webster Cordis

DePuy SynthesEnergy Sealing and

DissectingHernia Mesh & FixationDiabetes Care Ligation

Mentor One Touch Power SolutionsMicrowave Ablation Surgical Stapling

Vascular Access and

Infection ControlWound ClosureUterine & Pelvic

Source : DRAUP

5

5

Johnson & Johnson – Executive Leadership

Joaquin DuatoVice Chairman of the Executive Committee

Peter FasoloExecutive Vice President, Chief Human Resources

Officer

Ashley McEvoyExecutive Vice President, Worldwide Chairman,

Medical Devices

Jennifer TaubertExecutive Vice President, Worldwide Chairman,

Pharmaceuticals

Michael SneedExecutive Vice President, Global Corporate Affairs &

Chief Communication Officer

Paul StoffelsVice Chair of the Executive Committee and Chief

Scientific Officer

Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018.

Alex Gorsky

Chairman, Board of Directors &

Chief Executive Officer

Jorge MesquitaExecutive Vice President, Worldwide Chairman,

Consumer

Michael UllmannExecutive Vice President, General Counsel

Kathy Wengel Executive Vice President & Chief Global Supply Chain

Officer

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Source : DRAUP

6

6

KEY STRATEGIC PRIORITIES: Core Business Initiatives & Organisational Restructuring

• On September 12, 2018 Johnson & Johnson Medical Devices through its subsidiary Johnson & Johnson Medical GmbH acquired Emerging Implant Technologies GmbH (EIT), a privately held

manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery that allowed DePuy Synthes to enhance its comprehensive interbody implant portfolio that includes expandable

interbody devices, titanium integrated PEEK technology and now 3D-printed cellular titanium, for both minimally invasive and open spinal surgery.

• On July 30, 2018 Johnson & Johnson Consumer Inc. acquired Zarbee’s, Inc., a privately held company that is a leader in naturally-based healthcare products to bring a more comprehensive set

of products to consumers within their core need states.

• On June 12,2018 Johnson & Johnson announced that it has accepted the binding offer from Platinum Equity, to acquire its LifeScan, Inc., a world leader in blood glucose monitoring and maker

of the OneTouch® brand of products to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses

• On June 6, 2018 Johnson & Johnson announced that it has received a binding offer from Fortive Corporation to acquire its Advanced Sterilization Products (ASP) business, a division of

Ethicon, Inc to deliver the greatest value to customers, healthcare providers and shareholders.

• On May 2,2018 Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, acquired BeneVir Biopharm, Inc., a privately-held, biopharmaceutical company

specializing in the development of oncolytic immunotherapies which focused to bring forward an array of novel immunotherapies and combinations that might improve treatment outcomes for

patients.

• On February 20, 2018 Johnson & Johnson Medical Devices Companies acquired Orthotaxy, a privately-held developer of software-enabled surgery technologies to build a next-generation

robotic-assisted orthopaedic surgery solution that is cost-effective, time-efficient, and user-friendly in a variety of care settings

Note – Analysis is based on the news articles, journals and other similar sources updated in October, 2018

• On August 8, 2018 Johnson & Johnson announced the appointment of Chris DelOrefice as Vice President of Investor Relations to provide strategic financial leadership and counsel.

• On June 22, 2018 Johnson & Johnson announced the appointment of Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals and Dr. Paul Stoffels, Executive Vice

President, Chief Scientific Officer to the position of Vice Chairman of the Executive Committee

Organisational Restructuring

Core Business Initiatives

Source : DRAUP

7

7

KEY STRATEGIC PRIORITIES: Focus on Emerging Technologies & Ecosystem Partnerships

Focus on Emerging Technologies


• On September 26, 2018 Johnson & Johnson announced that DePuy Synthes introduced

SENTIO MMG, a first-of-its-kind digital mechanomyography platform designed to assess

nerve status and identify and avoid peripheral nerves during spine surgery.

• On June 7, 2018 DePuy Synthes, part of the Johnson & Johnson Medical Devices

Companies announced the launch of its Femoral Recon Nail System, a nailing system that

provides new options for the surgical treatment of a wide variety of long thigh bone fractures.

• On April 26,2018 DePuy Synthes, part of the Johnson & Johnson Medical Devices

Companies announced the US launch of the PROTI 360° Integrated Titanium Family of

interbody devices to advance care for patients who have degenerative disc disease in the

neck and back.

• On April 11, 2018 Johnson & Johnson Vision announced ACUVUE OASYS® with

Transitions® Light Intelligent Technology™ first of its kind contact lens that provides

wearers with vision correction and a dynamic photochromic filter that helps to continuously

balance the amount of light entering the eye

• On April 5, 2018 Johnson & Johnson Institute added a Innovative Analytics-Based

Learning Platform , a new digital learning capability to help surgeons improve technical

skills and clinical outcomes Across a Range of Specialties

• On September 23, 2018 Johnson & Johnson collaborated with Janssen Vaccines &

Prevention B.V., part of the Janssen Pharmaceutical Companies to develop and

manufacture a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-

CoV).

• On August 7, 2018 Johnson & Johnson Services Inc. partnered with the Government of

Rwanda to significantly strengthen and expand access to quality mental health care in the

country

• On April 16, 2018 The Janssen Pharmaceutical Companies of Johnson & Johnson

collaborated with Bristol-Myers Squibb Company on a program to develop and

commercialize Factor XIa (FXIa) inhibitors, including BMS-986177 for the prevention and

treatment of major thrombotic conditions.

• On February 7, 2018 The Janssen Pharmaceutical Companies of Johnson &

Johnson collaborated with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a

first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the

treatment of inflammatory bowel disease (IBD), which includes Crohn’s disease and

ulcerative colitis (UC).

• On December 21, 2017 Janssen Biotech, Inc. collaborated with Legend Biotech USA Inc.

and Legend Biotech Ireland Limited, subsidiaries of Genscript Biotech Corporation, to

develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug

candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA).

Ecosystem Partnerships

Source : DRAUP

8

8

AGENDA

➢ Details on Global Technology Footprint

❑ Key buying locations

❑ Region wise insights for global Technology centres – Headcount,

Activities and key products developed

Account Profile




Rolodex04

Recommendations05

01

02

03

Source : DRAUP

9

9

Key Buying Locations

➢ Key buying center is based out of Greater New York Area, United States

➢ Greater New York Area, United States with ~16% of engineering talent, is responsible for the development, maintenance

and execution of test scripts/ test cases for System integration test across test phases based on business requirements,

functional requirement specification and User stories

Key Engagements

➢ The Key activities are definition, implementation and maintainenance of program management strategies, procedures,

processes, and methodologies.

➢ Establishment and maintainenance of a Global Pharma Application/Service Asset & Configuration Management (SACM)

Governance process.

➢ Development of a of Tolerance Analysis System using TADM (Tolerance Analysis and Dimensional Management) System and

Enventive®

➢ Development and implementation of multi-region projects that drive strategic plan objectives for high growth of Clean & Clear®,

Beauty Devices, and the broader Johnson & Johnson® Face Care portfolio of brands.

Key StakeholdersMargaret Yu

Vice President, Oncology Clinical

Development

Dan BakerVice President Immunology

R&D

Kendra HilemanVP, Head of Clinical R&D

Daniel ZelemChief Technology Officer

Summary: Johnson & Johnson – Technology Globalization Footprint


Source : DRAUP

10

10

Global Technology Footprint of Johnson & Johnson

22Total Number of Technology Hotspots

3,000 – 4,000Total Number of Technology workforce

Installed

1Number of Buying Centers

Note – The represented data has been collected from Draup Proprietary Global Footprint Database updated as of October, 2018.

Note: The represented data illustrates the number of centers by Geography and the bubble size is proportional to overall HC Installed in the area.

No. of Centers : 1

Head Count : 30 – 60

Ireland

No. of Centers : 14

Head Count : 2K – 3K

No. of Centers : 1


No. of Centers : 2


Johnson & Johnson : Greater New York Area, United States is the only Key Buying Center that owns 100% of total Outsourced deals

United

States of

America

Switzerland

No. of Centers : 1


UK

No. of Centers : 1


Germany

No. of Centers : 1


Israel

China

No. of Centers : 1


Netherlands

Source : DRAUP

11

11

Outpost

Satellite

Hub

Note – The represented data has been collected from Draup Proprietary Global Footprint Database updated as of October, 2018.

Johnson & Johnson : Greater New York City Area, United States is one of the major Engineering hubs that owns ~16% of total Technology Workforce

Inverness Area

Greater New York City

Ireland

Cincinnati Area

Orange Country

Greater Philadelphia Area

Jacksonville, Florida

San Francisco Bay Area

Leeds Area

Israel

SwitzerlandGreater Boston Area

Greater Los Angeles

Hamburg Area

Fort Wayne, Indiana AreaMiami/Fort Lauderdale

Suzhou, China

Albuquerque, New Mexico Area

Groningen Area

San Angelo, Texas Area

Madison, Wisconsin Area

Providence, Rhode Island Area

Source : DRAUP

12

12

Location


Area, United States

R&D Headcount

500 – 600 FTEs

Center Level

Hub, HQ

Average Salary Cost / FTE

USD 115K / Annum

• Creation of Python-Flask REST API’s health-check endpoints to fetch data from HashiCorp Consul for granular

level monitoring Web, DB, Node.js app services to showcase real time statistics on Grafana Dashboard.

• Implementation of TDD/BDD approach for developing the Python applications, unit-tested by mocking for external

resources like AWS S3 Bucket, DynamoDB, VMware vRealize Orchestrator's API's slashing resource.

• Development of innovative plastic surgery implants, reconstruction & augmentation silicone based implants

• Validation of data on front end as well as Back end (Writing Sql Query).

• Development of biochemical and physical assays to characterize formulations of novel medical devices.

• Mechanical device design and development for Wound Closure and Repair, Hernia, and Bio surgery businesses

Top leaders


MaryJo ZaborowskiVice President, R&D IT

Major Engineering Talent Profiles

Senior Data

analyst

Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018

Greater New York City Area, United States – Technology Centre Deep Dive: Centre Overview

Software

Engineer

Source : DRAUP

13

13

Technology Leadership

42 Key Executives (Including, Top Leaders, VPs and Directors)

Top Leaders

Vice president’s


Bernhard BrouwerVP IT - Consumer NA + global

R&D

Norm RosenthalVP, Clinical Development,

Cardiovascular & Metabolism

Josh GhaimChief Technology Officer at

Johnson & Johnson


Katia BovenVP, Clinical Development and

Global Medical Affairs

San Francisco Bay Area, United States – Technology Centre Deep Dive: Technology Leadership (1/3)


Sen Zhuang MDVice President, Oncology

Clinical Research

Vaibhav NarayanVP Research and Therapeutic

Area IT

Walter JoppyVP Global IT Quality &

Compliance

Lynn ReedVP, Information Technology,

Application Services

Jonathan MillerVP Global Oral Care & Wound

Care R&D

Gunaretnam RajagopalVP - Global Head,

Computational Sciences,

Discovery Sciences

Samantha Tucker-

SamarasVP, Strategic Science R&D

Jennifer ZhuVice President, Global Beauty

R&D

Source : DRAUP

14

14



Vice President’s


Federico Feldstein, JDVice President, Head of R&D

Quality & Compliance

David GruberVP, Corporate Development &

New Ventures

Leona Brenner- GatiVice President, Science and

Technology

Keith DemarestVice President, Global Head of

Research


Director’s

Nicholas Di ProsperoSenior Director, Clinical

Development

Muneet BurkeDirector - Medical Safety Officer

Christoph HeuckSenior Director Clinical

Research

Mehul DesaiSenior Director Clinical

Development

Om Sharma, MSDirector, Clinical Research and

Drug Development

Eunice Ofori ArtisDirector, Clinical Research

Rafal HRYMOCDirector - Global R&D Beauty

Packaging & Innovation

Carolyn MordasSenior Director R&D

Jacqueline BussolariSenior Director, Development

Team (Oncology)

Phil Rudio, PEGlobal Director, Engineering and

Design

Filomena MacedoSenior Director R&D Skin Care

Theresa ScheubleDirector, R&D

Michael SmithSenior Director, Compound

Development Team

Charles J. BuckleDirector of Engineering

Rochelle KleinbergDirector, Healthcare Solutions

Chris KarcherDirector, Enabling Technology

Source : DRAUP

15

15





Director’s

Cokey N.Senior Director, Oncology R&D

Mayra GoncalvesSenior Director R&D

George QuirkSenior Director, Engineering

Network

Ying WanDirector, Oncology Clinical

Biostatistics

John MurthaDirector Material Science &

Technology

Steven GabelDirector, Engineering

Carol BoyneSenior Director R&D

Pat CalaiaroDirector, R&D Operations

Source : DRAUP

16

16

DETAILSLOCATIONR&D

HEADCOUNT


Area, United States500 – 600

• Development of Jenkins CICD pipelines, automating deployments for (AWS & Bare metal VM’s), integration with GIT to

automate code-checkout and release processes.

• Involved in Research and Development of Sutures including Antibacterial Sutures

Greater Philadelphia


• Product development of digital solutions for the Johnson & Johnson Diabetes Care companies, including LifeScan Inc.,

Animas Corporation, and Calibra Medical, Inc

• Design and develop implants and instrumentation for orthopaedic applications

Cincinnati Area,

Kentucky, United

States

300 – 400

• Supports the Ethicon Portfolio of Products in J&J Medical Devices.

• Design and development of Harmonic products in the Energy business

• Development of bipolar and ultrasonic algorithms for optimum tissue sealing effects

Jacksonville, Florida


• Design and management of biomarker discovery for ophthalmic indications and contact lens derived adverse events.

• Leads and manages the Global R&D Lab Systems Production Line.

• Product development in spherical daily disposable and reusable lenses, lenses for astigmatism, lenses for presbyopia,

and lenses for natural beauty enhancement

Switzerland 200 – 250• Validation of Equipment Process/Aseptic Process Simulation in Life Cycle Management of Parenterals Production.

• Development of products for cervical spine treatment & Cervical R&D

Ireland 200 – 250

• Development, testing and installation of control system software changes with supporting documentation for validating

the manufacturing systems.

• Development and execution of test plans (SAT, FAT).

Globalization Technology Footprint (1/4)

Note – Global Footprint data curated by DRAUP and updated in October, 2018. R&D Headcount includes research and product engineering talent

Buying Centres

Source : DRAUP

17

17

DETAILSLOCATIONR&D

HEADCOUNT

Greater Boston Area,

United States100 – 200

• Development of new and novel Spinal systems including MIS Pedicle Screws, Power, Navigation, Expandable Cages, 3D

Printed cages and Lateral Systems.

• Involved in Process Development for Health Care Products

Greater Los Angeles


• Development of the Clean & Clear® brand by ensuring global consistency in Generation Z equity understanding,

positioning, new product idea generation to drive the business growth.

• Identify and capitalize on key macro trends for leading key global strategic Face Care initiatives

Orange County,

California Area, United

States

100 – 200

• Validation of Enterprise systems with preparation and execution of validation deliverables. Supports Product Quality

NPI/LCM projects.

• Development of test methods, creates protocols and analyses data.

Inverness, United

Kingdom100 – 150

• Validation and Verification of high-tech automated manufacturing line of networked machines.

• Creation and execution of validation documents, specifically factory acceptance testing protocols.

• Deployment of strategic NPI’s & Supply Chain projects into the organisations product portfolio.

San Francisco Bay


• Involved in end-of-life mitigation, service escalations and cost improvement projects for on-market products.

• Involved in PCBA design changes for product yield improvement

Hamburg Area,

Germany50 – 100

• Planning, implementation & sustainability of process improvements in relation to material and productivity losses of a

surgical sutures production area.

• Supports QMS related projects such as integrating the EES GmbH Quality System into the Ethicon Quality System.



Source : DRAUP

18

18

DETAILSLOCATIONR&D

HEADCOUNT

Leeds, United Kingdom 50 – 100

• Development of appropriate orthopaedic medical devices specifically for the ASPAC region.

• Management of the project from the front end, charter, development, verification and validation through to eventual

commercialisation

Israel 50 – 100

• Development of firmware for a generator device used for Cardiac ablation procedure.

• Design, development & implementation of Software & Architecture for Advanced Networking and Wireless Devices in

embedded platforms

Fort Wayne, Indiana


• Development of New technology and involved in next generation biological fixation.

• Design/optimize stainless steel surgical instruments for 3D Printing.

• Planning and designing of Post processing of parts for machining, heat treatment and use of finishing technologies.

Miami/Fort Lauderdale


• Design and maintainenance of ETL processes and data warehouse.

• Development and implementation of processes, procedures, audits and corrective actions.

• Design and implementation of machine safeguards.

Suzhou, China 30 – 60

• Creating 3D models, drawings, DFMEA and DHF.

• Designing of global joint to meet the need and requirement of Chinese market and performs unique product development

process to create domestic product codes with high standard drawings

Albuquerque, New

Mexico Area, United

States

10 – 30• Involved in several different product lines and all New Product Development launches.

• Development of diagnostic technologies for refractive & cataract surgery and contact lenses.



Source : DRAUP

19

19

DETAILSLOCATIONR&D

HEADCOUNT

Groningen Area,

Netherlands10 – 30

• Development of Intraocular lenses for cataract surgery.

• Performs overall QA activities in a medical devices company with slight focus on Quality Management System.

San Angelo, Texas


• Testing and inspection of the quality of chemical compounds, reagents and culture media.

• Development and implementation of the Reliability and Maintenance Engineering Department.

Madison, Wisconsin


• Testing and running of protocols that help characterize performance of NeuWave technology.

• Involved in new product launch to accelerate the business growth.

Providence, Rhode

Island Area, United

States

10 – 20

• Development and delivery of multiple Android platforms including Care4Today Connect, the J&J Official 7 Minute

Workout, and applications developed for the Care Module platform.

• Automation of regression tests for numerous company projects using JBehave /Java, and similar tools.



Source : DRAUP

20

20

AGENDA

➢ Outsourcing Vendor’s deals analysis

❑ Total headcount outsourced to service providers

❑ Key vendors working with Johnson & Johnson

❑ Key Opportunity areas to target

Account Profile




Rolodex04

Recommendations05

01

02

03

Source : DRAUP

21

21

Summary: Technology Services Outsourcing

Key partners

Key Activities

➢ Product Engineering Services is the key engagement areas for Johnson & Johnson contributing to 55% of total outsourced

deals

➢ Major workloads across Product Engineering Services is development & Testing of some mobile application like Nicorrete,

mentor App etc.,

➢ Involved in Adhoc Testing, Sanity Testing, Functional Testing and Regression testing.

Note: Analysis is based on the news articles, journals etc updated in October, 2018

Key Opportunity Areas➢ Vendors should target on Product Engineering Services related engagements

➢ Vendors can also target on Artificial Intelligence (AI) for the discovery of Drugs

➢ HCL is the major strategic partner for Johnson & Johnson working majorly across the area of PES, ADM and IMS. HCL

contributing to ~40% of total outsourcing size

➢ TCS is other key outsourcing partner contributing to nearly ~30% of the current outsourced deals

Source : DRAUP

22

22

HCL 40%

TCS 30%

Cognizant 12%

Capgemini, 9%

Sonata Software, 5%

IBM, 2%Wipro, 2%

Technology Outsourcing Split by Service ProvidersSplit by Sub Service Segment (In HC %)

400 - 450 Workforce split across

Outsourcing Partners

7 Active Outsourcing Partners

Note - Above analysis is based on the DRAUP’s proprietary Outsourcing module, updated in October, 2018.

Vendor Analysis – HCL is the major strategic partner for Johnson & Johnson contributing to 40% of total outsourced HC

Source : DRAUP

23

23

ADM and IMS Sub-segments has the highest number of deals with multiple vendors

Note - Above analysis represents the HC split of Service Providers in each Sub-segment for Johnson & Johnson updated in October, 2018

Cognizant, 46% HCL, 18% Sonata Software, 9% TCS, 18% Wipro, 9%

Cognizant HCL Sonata Software TCS WiproADM

Capgemini, 17% HCL, 17% IBM, 17% Sonata Software, 17% TCS, 32%

Capgemini HCL IBM Sonata Software TCSIMS

PES

Capgemini, 13% HCL, 60% TCS, 27%

Capgemini HCL TCS

TCS, 100%

TCSCSI

Source : DRAUP

24

24

Key Vendor Engagements Snapshot (1/3)


Split of Workforce by Sub Segment

PES :

• Designing, Testing, development & Maintenance of pheonix STNX

• Implementation of 3D Model design & evaluation

ADM :

• Involved in executing the Test Protocols

• Preparation of Test Protocol for the verification testing

IMS:

• Monitoring batch jobs using SCOM,NETCOOL and NCS Alert board

• Installation of Windows & Unix agent, Cluster package (Windows & Unix).

HC

100 – 200

Key Delivery Locations

Delhi, Madurai, Chennai

ADM, 12% IMS, 6% PES, 82%


ADM:

• Involved in implementing UI changes

• Development of functional specifications document and technical design document

CSI:

• Development of POC for S&OP & supply chain visibility using SAP IBP

• Creation of Information Models like Attribute View, Calculation View, Analytic View

PES:

• Development & testing of some mobile application like Nicorrete, mentor App etc

• Supports the US FDA Submission batches

IMS:

• Development of Tcl & SQL scripts to generate reports and modify data as per requirements as post-load activity

HC

100 – 150


Bengaluru,

Bhubaneshwar, Kolkata

ADM, 16% CSI, 16% IMS, 16% PES, 52%

Source : DRAUP

25

25



ADM:

• Involved in System, Integration, Automation, Regression and Mobile Testing

• Development of HTML Pages for Ipad Compatibility and Page Level interactions

ADM, 100%


PES:

• Enhancement & Support for web based applications

• Development, Testing, upgradation for JNJ products like GEN11 devices, Ethicon App

IMS:

• Involved in Data Modelling, Data Quality and loading strategy

HC

20 – 40


Bengaluru

IMS, 25% PES, 75%


ADM:

• Debugs the test scripts to identify the scripts errors and fix the errors

• Enhancement of automation framework and updating the test scripts based on the changes in the received in different sprints

IMS:

• Designing the test Cases for validating JJAR database

• Testing JJAR reports and validating the data in reports

HC

10 – 20


Hyderabad, Bengaluru

ADM, 50% IMS, 50%


HC

30 – 60


Bengaluru, Howrah

Source : DRAUP

26

26




ADM:

• Development of RFP Import from GB to Ariba Buyer

• Involved in Application Packaging and Integration

• Development of web services to call web method from Infosys’ Procure Edge to Ariba

HC

10 – 20


Bengaluru

ADM, 100%


IMS:

• Involved in agile sprint planning and story grooming sessions

• Development of the mapping/ sessions/ workflows for learning assignment module

• Involved in performance tuning issues at various levels such as target, sessions, mappings and sources

HC

10 – 20


Kolkata

IMS, 100%

Source : DRAUP

27

27

AGENDA

➢ Key Technology Stakeholders

❑ Key Technology stakeholders & Leadership

Account Profile




Rolodex04

Recommendations05

01

02

03

Source : DRAUP

28

28

Johnson & Johnson – Technology Leadership (1/2)

Norm RosenthalVice President, Clinical Development,

Cardiovascular & Metabolism

Philippe SzaparyVice President, Immunology Clinical

Development

Michael EppihimerVice President of Preclinical Research

Bernhard BrouwerVP IT - Consumer NA + global R&D

Katia BovenVice President, Clinical Development

and Global Medical Affairs, Infectious

Diseases

Daniel Zelem

Chief Technology Officer

Margaret YuVice President, Oncology Clinical

Development


Ian McCafferyVice President, Head Oncology

Translational Research

Jeremy YarwoodVice President of Research and

Development, Advanced Sterilization

Products


Vaibhav NarayanVP Research and Therapeutic Area IT

Julian BertschingerVP, Head Therapeutic Platform

Innovation

Kendra HilemanVP, Head of Clinical R&D

Dave SmithVice President, Global Research and

Development

Sal TrovatoVice President, Corporate IT Global

Product Line

Dirk GilleVP R&D Fellowship Development

Leader

Sen ZhuangVice President, Oncology Clinical

Research

Anastasia ChristiansonVice President, R & D Operations and

Oncology IT

JD AlvarezVice President and Head, Oncology

Diagnostics

Samantha Tucker-SamarasVice President, Strategic Science R&D

Scott PlevyVice President, Immunology Research

and Development

Source : DRAUP

29

29

Johnson & Johnson – Technology Leadership (2/2)

David GruberVP, Corporate Development & New

Ventures


Leona Brenner-GatiVice President, Science and Technology

Brian WoodfallVice President, Global Clinical

Development

Vake JozefVice-President Non-Clinical Development

Bonnie SiegelVice President Information Technology

Bob RadinskyVice President, Oncology Scientific

Innovation

Kiran PatelVice President Clinical Development

Gopi ShankarVice President & Head, Biologics

Development Sciences

Dan BakerVice President Immunology R&D

David WoodsVP of Product Engineering, Health

Technology

Martin Madden Vice President, Research & Development,

and Innovation

Peter CorsoVice President, Information Technology,

Medical Devices Global Product Lines

Federico FeldsteinVice President, Head of R&D Quality &

Compliance

Claudia HerbenVice President IT and CIO Medical

Device

Kenny SimmenVP - Infectious Diseases & Vaccines

Ian AndersonSenior Vice President Immunology

Discovery and Scientific Innovation

Patricia Andrade-GordonVice President Early Development

Keith DemarestVice President, Global Head of Research

Source : DRAUP

30

30

AGENDA

➢ Key Opportunities

❑ Orthotaxy’s technology

❑ AI Drug Discovery

Account Profile




Rolodex04

Recommendations05

01

02

03

Source : DRAUP

31

31

By analysing Johnson & Johnson focus, DRAUP has identified the following key opportunity areas

Key Opportunity Segments

Note - Above analysis is based on the DRAUP’s proprietary services module, updated in October, 2018.

By the acquisition of Orthotaxy Johnson & Johnson

continues the development of the differentiated

robotic-assisted tool first for total, partial knee

replacement and also for multiple orthopaedic

surgery procedures such as spinal fusion surgery

Johnson & Johnson is planning to expand

Orthotaxy’s technology into other orthopaedic

surgeries as part of its bid to create a new robot-

assisted to personalize procedures, optimize

surgery and also to bring value to customers and

patients

Orthotaxy’s Technology

Johnson & Johnson invested up to $1M in

Artificial Intelligence for Drug Discovery

QuickFire Challenge as AI poses unlimited

opportunity for J&J to make a transformative impact

on patients.

Janssen Research & Development found a new

way to leverage artificial intelligence (AI) by

using computer systems and also teamed up with

academic partners from leading European

universities to develop computer algorithms

AI Drug Discovery

Source : DRAUP

32

32

https://twitter.com/zinnov

http://facebook.com/ZinnovManagementConsulting

https://www.linkedin.com/company-beta/30724/

https://www.youtube.com/channel/UCgEN1J9L2jTqBOlWsH65w8w

http://www.zinnov.com/

mailto:[email protected]?subject=How can we help you?

http://www.draup.com/

https://twitter.com/zinnov

http://facebook.com/ZinnovManagementConsulting

https://www.linkedin.com/company-beta/30724/

https://www.youtube.com/channel/UCgEN1J9L2jTqBOlWsH65w8w

mailto:[email protected]?subject=How can we help you?

johnson & johnson account deep dive analysis - amazon s3 · johnson & johnson –account...

Documents